Geron inks $935m Janssen deal after clinical hold lift

Geron will get $35m up front and may earn up to $900m in milestone fees plus royalties on future sales of the telomerase inhibitor imetelstat under the biotechnology company's worldwide license and collaboration agreement with Johnson & Johnson's Janssen Biotech subsidiary.

Geron will get $35m up front and may earn up to $900m in milestone fees plus royalties on future sales of the telomerase inhibitor imetelstat under the biotechnology company's worldwide license and collaboration agreement with Johnson & Johnson's Janssen Biotech subsidiary.

November has been a good month for Menlo Park, California-based Geron, since the US FDA recently lifted a full clinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category